ABMC — American Bio Medica Income Statement
0.000.00%
Last trade - 00:00FinancialsHighly SpeculativeMicro Cap
- $0.00m
- $0.11m
- $0.91m
Annual income statement for American Bio Medica, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.87 | 3.65 | 4.15 | 2.22 | 0.913 |
| Cost of Revenue | |||||
| Gross Profit | 1.29 | 1.18 | 1.24 | 0.548 | -0.103 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 4.63 | 4.25 | 4.77 | 3.16 | 2.15 |
| Operating Profit | -0.762 | -0.593 | -0.621 | -0.944 | -1.24 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.03 | -0.686 | -0.794 | -0.461 | -1.41 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.03 | -0.681 | -0.796 | -0.463 | -1.41 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.03 | -0.681 | -0.796 | -0.463 | -1.41 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.03 | -0.681 | -0.796 | -0.463 | -1.41 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.034 | -0.021 | -0.022 | -0.014 | -0.029 |